| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -31.1 | -47.7 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: LRMR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Larimar Therapeutics, Inc.: key numbers
- Share price
- $3.00Close, Nov 16
- Market cap
- $314M
- Shares outstanding
- 104.63MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Larimar Therapeutics, Inc.
All →Larimar Therapeutics Financial Results
Larimar Therapeutics reported third quarter 2026 financial results and announced the completion of its rolling BLA submission to the FDA for nomlabofusp in Friedreich’s ataxia. The company ended the quarter with $128.7 million in cash, providing a projected runway into late Q2 2027 as it prepares for a potential U.S. launch in Q3 2027.
“Completing the BLA submission for nomlabofusp marks a major milestone for Larimar and the Friedreich’s ataxia (FA) community. The next 12 months are expected to bring several pivotal registrational catalysts, including FDA review of our application and progression of FORWARD-FA, our global confirmatory Phase 3 study.”
Carole Ben-Maimon, M.D., Chief Executive Officer
“In parallel, we are preparing for a potential U.S. launch in the third quarter of 2027, if approved, while evaluating options to support global commercialization.”
Carole Ben-Maimon, M.D., Chief Executive Officer
Larimar Therapeutics Director Thomas Edward Hamilton Buys $187K of Stock
Thomas Edward Hamilton, Director, bought 70,000 shares of Larimar Therapeutics, Inc. at $2.67 a share, worth $187K in total on Nov 12, 2026. Shares held after the trade: 70,000.
- Value
- $187K
- Shares
- 70,000
- Price
- $2.67
- Role
- Director
- Trade date
- Nov 12, 2026
Larimar Therapeutics President and CEO Carole Ben-maimon Buys $50K of Stock
Carole Ben-maimon, President and CEO, bought 18,050 shares of Larimar Therapeutics, Inc. at $2.77 a share, worth $50K in total on Nov 11, 2026. Shares held after the trade: 386,326 (+4.9%).
- Value
- $50K
- Shares
- 18,050
- Price
- $2.77
- Role
- President and CEO
- Holding change
- +4.9%
- Trade date
- Nov 11, 2026
Larimar Therapeutics Director Frank E. Thomas Buys $21.8K of Stock
Frank E. Thomas, Director, bought 8,000 shares of Larimar Therapeutics, Inc. at $2.73 a share, worth $21.8K in total on Nov 11, 2026. Shares held after the trade: 15,000 (+114.3%).
- Value
- $21.8K
- Shares
- 8,000
- Price
- $2.73
- Role
- Director
- Holding change
- +114.3%
- Trade date
- Nov 11, 2026
Larimar Therapeutics President and COO John B. Harlow Jr. Buys $49.9K of Stock
John B. Harlow Jr., President and COO, bought 17,800 shares of Larimar Therapeutics, Inc. at $2.80 a share, worth $49.9K in total on Nov 11, 2026. Shares held after the trade: 67,800 (+35.6%).
- Value
- $49.9K
- Shares
- 17,800
- Price
- $2.80
- Role
- President and COO
- Holding change
- +35.6%
- Trade date
- Nov 11, 2026
Larimar Therapeutics CFO Michael Celano Buys $50K of Stock
Michael Celano, CFO, bought 18,460 shares of Larimar Therapeutics, Inc. at $2.71 a share, worth $50K in total on Nov 11, 2026. Shares held after the trade: 234,245 (+8.6%).
- Value
- $50K
- Shares
- 18,460
- Price
- $2.71
- Role
- CFO
- Holding change
- +8.6%
- Trade date
- Nov 11, 2026